News | Computer-Aided Detection Software | January 22, 2020

The final order reclassifies certain CADe devices from Class III to Class II devices, subject to premarket 510(k) notification

he U.S. Food and Drug Administration (FDA) has issued a final order to reclassify medical image analyzers applied to mammography breast cancer, ultrasound breast lesions, radiograph lung nodules and radiograph dental caries detection, postamendments class III devices (regulated under product code MYN), into class II (special controls), subject to premarket notification

Image courtesy of iCAD


January 22, 2020 — The U.S. Food and Drug Administration (FDA) has issued a final order to reclassify medical image analyzers applied to mammography breast cancer, ultrasound breast lesions, radiograph lung nodules and radiograph dental caries detection, postamendments class III devices (regulated under product code MYN), into class II (special controls), subject to premarket notification. These devices are intended to direct the clinician's attention to portions of an image that may reveal abnormalities during interpretation of patient radiology images by the clinician. FDA is also identifying the special controls that the Agency believes are necessary to provide a reasonable assurance of safety and effectiveness of the device type. The order will be effective Feb. 21, 2020. 

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, establishes a comprehensive system for the regulation of medical devices intended for human use. Section 513 of the FD&C Act (21 U.S.C. 360c) established three classes of devices, reflecting the regulatory controls needed to provide reasonable assurance of their safety and effectiveness. The three classes of devices are class I (general controls), class II (special controls), and class III (premarket approval).

Devices that were not in commercial distribution prior to May 28, 1976 (generally referred to as postamendments devices), are automatically classified by section 513(f)(1) of the FD&C Act into class III without any FDA rulemaking process. Those devices remain in class III and require premarket approval unless, and until, the device is reclassified into class I or II, or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the FD&C Act, to a predicate device that does not require premarket approval. The Agency determines whether new devices are substantially equivalent to predicate devices by means of premarket notification procedures in section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and part 807 (21 CFR part 807).

A postamendments device that has been initially classified in class III under section 513(f)(1) of the FD&C Act may be reclassified into class I or II under section 513(f)(3). Section 513(f)(3) of the FD&C Act provides that FDA acting by order can reclassify the device into class I or II on its own initiative, or in response to a petition from the manufacturer or importer of the device. To change the classification of the device, the proposed new class must have sufficient regulatory controls to provide a reasonable assurance of the safety and effectiveness of the device for its intended use.

On June 4, 2018 (83 FR 25598), FDA published in the Federal Register a proposed order to reclassify the device type from class III to class II, subject to premarket notification. The comment period on the proposed order closed on August 3, 2018.

You can read the full published final order here


Related Content

News | RSNA

May 29, 2024 — The Radiological Society of North America (RSNA) has launched the 2024 RSNA Lumbar Spine Degenerative ...

Time May 29, 2024
arrow
News | Breast Imaging

May 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time May 28, 2024
arrow
News | Enterprise Imaging

May 24, 2024 — International medical imaging IT and cybersecurity company Sectra’s enterprise imaging solution has been ...

Time May 24, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
News | Enterprise Imaging

May 16, 2024 — AGFA HealthCare announced that St. Vincent’s Private Hospital in Dublin, Ireland, has chosen to implement ...

Time May 16, 2024
arrow
News | Artificial Intelligence

May 16, 2024 — deepc, the globally recognized digital medicine pioneer and market leader behind the leading AI operating ...

Time May 16, 2024
arrow
Sponsored Content | Case Study | Enterprise Imaging

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
News | Enterprise Imaging

May 15, 2024 — etherFAX has announced the expansion of its partnership with Hyland, a global provider of intelligent ...

Time May 15, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Cybersecurity

May 13, 2024 — In the wake of the cybersecurity breach targeting the prominent healthcare system Ascension, a new study ...

Time May 13, 2024
arrow
Subscribe Now